Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Apogee Therapeutics Inc APGE

Healthcare Biotechnology
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:APGE)

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

GlobeNewswire 7 days ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

GlobeNewswire 7 days ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

GlobeNewswire May 1, 2025

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

GlobeNewswire March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

GlobeNewswire March 3, 2025

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

GlobeNewswire February 28, 2025

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 25, 2025

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

GlobeNewswire February 3, 2025

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire January 29, 2025
View More News ››

Opinion & Analysis (NDAQ:APGE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:APGE)

Reshaping the Standard of Care in Inflammatory and Immunolog

Looks like APGE is making some serious moves in the inflammatory disease space. Their APG777 with a 75-day half-life is pretty impressive...
MikeTester - January 24, 2025
View more Bullboard ››

Lode Gold Resources Inc.

Lode Gold Resources Inc.

Lode Gold Resources Inc. is a Canadian exploration and development company with grassroots and advanced exploration ...
View More »